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Background: The aim of the present study is to test in the feasibility of a screening programme for HCV infection
in an Italian prison and to evaluate the treatment outcomes.
Method: Single-centre cross-sectional study carried out in Milan-Opera. The HCV infection prevalence was
calculated on the imprisoned population on the January 31 2006, the data on treatment over the following 2 years.
Treatment option offered to HCV chronically infected patients was then analysed, reasons for not being treated was
evaluated.
Results: Of the 965 inmates, 695 were enrolled in the study, 682 (98%) were males, the median age was 43 years.
There were 131 (18.8%) foreigners and 564 (81.2%) Italians. HCV seroprevalence was 22.4%(95% CI:19.4%-25.7%), 60
subjects (38.4%) being HIV co-infected too. Prevalence of HCV infection was significantly higher in HIVAb positive
(89.6%; 95% CI:79.7%-95.7%) than in HIVAb negative (15.15%; 95% CI 12.6%-18.3%) (p<0.001). Among Italian inmates
HCVAb positivity was significantly higher than among foreigners (p=0.0154). Among HCVAb positive patients, 135
subjects were HCV-RNA positive. Forty-seven (36%) had major clinical contraindication to treatment, 18 (13%)
refused the treatment, 7 (5%) moved to other Institute and 27 (20%) were not evaluated by infectious disease
specialists. Fifteen patients (43%) who received treatment were considered responders, 9 (26%) were non
responders/relapsers, 6 (17%) interrupted treatment due to side effects and 5 (14%) were released during treatment
and lost in follow-up.
Conclusions: This study indicates that the proportion of patients in a prison setting receiving diagnosis and
treatment for HCV infection remained low.
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HCV infection in prison inmates is widespread, surveys in
correctional system show an HCV sero-prevalence ranging
from 16% to 42% in U.S.A. [1], 30% to 50% in European
Countries [2] and 31% to 38% among Italian inmates [3,4].
As a consequence, several national authorities published
guidelines which recommend testing each incoming in-
mate for blood transmitted diseases. In the 16/04/2000 act
issued to preserve health in correctional settings [5], the* Correspondence: e.seminari@smatteo.pv.it
1Clinica di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Viale
Camillo Golgi 19, 27100 Pavia, Italy
Full list of author information is available at the end of the article
© 2013 Brandolini et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orItalian Ministry of Health made it necessary not only to
test and treat all intra-venous drug abuse associated infec-
tions but also to promote educational programs to improve
prison inmate awareness on preventive measures and
therapeutic needs, as a result HCV screening should be
offered to all inmates at admission. On the other hand, in a
real life setting, due to a complex array of local (in jail) and
national (Italian Ministry of Justice) organization deficits,
not always are inmates routinely tested for either hepatitis
virus and human immunodeficiency virus (HIV). An over-
whelming number of daily incoming prisoners, a shortage
of adequate health facilities and trained staff, continuous
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the main reasons which hindered the carrying out of
proposed acts.
Data on treatment of HCV chronic hepatitis in prisons
are limited to few observational studies [6-8], small case
series have been published in Italy on this specific topic
[9]. In general, only a minority of patients with hepatitis
C in prison can complete a full course treatment as early
patient’s release or side effects or concomitant patholo-
gies have limited the access to treatment [7,8].
The object of this study was firstly to evaluate the preva-
lence of HCV infection among prisoners and its epidemio-
logical correlates, secondly to estimate the number who
could be treated and HCV infected inmates who were actu-
ally treated, thirdly to calculate the number of sustained
virologic responders among those treated.
Methods
The study was designed as a single-centre cross-sectional
study and was conducted among inmates of a single, large
North Italian prison (Milan-Opera) where the vast majority
of inmates had been sentenced for a period longer than
three years. This prison was built to contain 750 inmates,
but actually more than a thousand (roughly 1200) people
are normally detained. It is split into male and female
sections (this last section was closed in 2010) with an inner
Clinical Centre with one medical ward, and an isolation
area for air born infection and two AIDS-wards.
Prevalence of HCV infection was calculated on the
imprisoned population on the January 31 2006, data on
treatment during the following 2 years. Data collection was
carried out in two steps. Firstly, all the inmates sanitary
records were reviewed to asses HCV sero-status. Secondly,
all the subjects either untested or with a previous negative
result of more than three years underwent HCV serology.
Among patients with positive HCV serology, it was evalu-
ated the prevalence of blood HCV RNA determination.
Treatment option offered to HCV chronically infected pa-
tients was then analysed, reasons for not being treated was
also evaluated. Lastly, among those treated, percentages of
responders and non responders to treatment were analysed.
The Ministry of Justice study approved the study and
granted an official waiver to proceed as data were col-
lected in accordance with the ethical standards, guaran-
teeing the anonymity of the results. All participants
signed an informed consent.
Statistical analysis
Categorical variables were described by means of count
and percentage, continuous ones by means of median and
range or interquartile range. Prevalence were given to-
gether with their 95% confidence interval (95% CI). Base-
line patients characteristics (age, gender, nation of birth
and HIV/HBV coinfection) were described for the overallsample and according to HCV infection. The Student’s
t test was used to compare continuous variables and the
Chi-square test was used to study the association between
categorical variables.
Logistic regression model was fitted with HCV infection
as dependent variable and nationality and age as independ-
ent variables. The statistical analysis was performed using
Stata v11 (StataCorp, College Station, TX, USA).
Results
Of the 965 inmates in Milan-Opera prison the day of sur-
veillance, 695 were enrolled in the study (either were
already tested for HCV in the previous three years (439
pts; 45.5%) or accepted to perform serological test (256 pts,
26.5%). Among the remaining 270 (28%) patient not tested,
137 resulted to be released at the time of blood test, 36
moved to another prison, 59 denied the consent to partici-
pate to the study, 1 patient deceased and 3 resulted to be
not tested despite they gave consent. For the remaining 34,
the reason of not being tested was unspecified. No demo-
graphic differences were observed between those tested
and not tested for HCV infection (Table 1).
Demographic characteristics of the 695 inmates tested
are summarized by Table 2. Percentages of women and
foreigners are comparable with those of Italian prisoner’s
population, respectively <5% and 13% [10].
HCV seroprevalence was 22.4% (95% CI: 19.4%-
25.7%) -156 subjects- with 60 subjects (38.4%) being
HIV co-infected too (Table 2). Prevalence of HCV infec-
tion was significantly higher in HIVAb positive (89.6%;
95% CI: 79.7%-95.7%) than in HIVAb negative (15.15%;
95% CI 12.6%-18.3%) (p<0.001). Median CD4+ cell
count in HIV/HCV confected subjects was 351 cell/
mm3 (interquartile range: 198–492 cell/ mm3).
Out of the 564 Italian inmates, 137 (24.5%; 95% CI
20.8%-28.0%) were HCVAb positive, among foreigners 19/
131 were HCVAb positive (14.5%; 95% CI: 9.0%-21.7%);
namely 12 (20.3%) out of 59 African inmates, 3 (6.4%) out
of 47 from East-Europe and 4 (16%) out of 25 Latino-
American were HCVAb positive. Among Italian inmates
HCVAb positivity was significantly higher than among for-
eigners (p=0.0154), this association remained statistically
significant after correction for age (OR 2, 95% CI 1.2-3.4;
p<0.01). In Italian inmates, HCVAb positivity was higher in
age classes between 35–42 and 43–52 years (37% and
28.7%, respectively) while was lower in age classes between
18–34 and 53–82 (18 and 12%, respectively), (p<0.001).
Out of the 13 women tested for HCVAb, 8 (61.5%) were
positive. Among HCVAb positive patients, 135 subjects
were HCV-RNA positive, 28 were HCV RNA negative and
13 did not perform any HCV RNA test (7 early release, 6
unknown) (Figure 1). Thirty-five (26%) subjects among
those HCV RNA positive were evaluated by infectious dis-
ease specialist and were elected to receive treatment with
Table 1 Demographic characteristics of patients tested and not tested for HVC Ab
All N=965 N(%) Tested for HCV infection N=695 N(%) Not tested for HCV infection N=270 N(%) p
Age mean (sd) 43.59 (11.99) 43.2 (11.18) 44.58 (13.83) 0.11
Males 944(97.82) 682 (98.13) 262 (97.04) 0.33
Females 21 (2.18) 13 (1.87) 8 (2.96)
Origin
Africa 92(9.53) 59 (8.49) 33 (12.22) 0.23
East Europe 67(6.94) 47 (6.76) 20 (7.41)
Italy 775(80.31) 564 (81.15) 211 (78.15)
other 31(3.21) 25 (3.6) 6 (2.22)
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contraindication to treatment (i.e. mental illness, cirrhosis,
cardiac disease, low CD4+ cell count in HIV+ subjects), 18
(13%) refused the treatment, 7 (5%) moved to other Insti-
tute and 27 (20%) were not evaluated by infectious disease
specialist. Fifteen patients (43%) who received treatment
were considered responders, 9 (26%) were non responders/
relapsers, 6 (17%) interrupted treatment due to side effects
and 5 (14%) were released during treatment and lost to
follow-up.
Discussion
The present study highlights the difficulties encountered
in a screening process for HCV in a prison setting, des-
pite dedicated personnel to this specific duty, roughly
30% of subjects did not receive the screening test,
eventually only a minority of them denied the consent to
participate. The problem of HCV infection in prison is
extensive and troublesome, but both in US and in Europe
[11,12], according to directives, correctional facilities
should seriously cope with the problem of HCV infection.
The CDC estimates that 12% to 35% of US inmates
had chronic HCV infection [12], the majority of theseTable 2 Demographic characteristics of patients HVC Ab posi
All N=695 N(%) HCV neg N=539 N(%)
Age mean (sd) 43.2 (11.18) 43.34 (11.71)
Origin
Africa 59(8.49) 47 (8.72)
East Europe 47(6.76) 44 (8.16)
Italy 564(81.15) 427 (79.22)
other 25(3.6) 21 (3.9)
Males 682 (98.13) 534 (99.07)
Females 13 (1.87) 5 (0.93)
HbsAg+ 30(6.22) 24 (5.81)
HIV+ 67(9.64) 7 (1.3)
* Logistic regression model fitted with HCV infection as dependent variable and napatients being represented by IVDU and/or tattooing
[13,14]. According to different studies, the burden of
HCV infected prisoners in Italy varies between 20 and
40%, therefore considering an inmate average number of
65000 [10], roughly 10000 to 20000 patients in prison
potentially need treatment (considering that roughly the
20% of patients testing antibody positive doesn’t need
treatment). These data emphasize the importance of sur-
veillance in prison [15], and counseling of patients
affected from HCV infection about prevention strategies
and treatment options [7,8].
The difficulties associated with HCV screening proce-
dures in a prison setting as Opera is, are principally related
to severe limitation due to a complex array of problems.
First, institutional regulations and organization which cause
the mobility of prisoners, who are moved from prison to
prison for different reasons such as trial in cities far from
the residence prison. Second, logistic problems (i.e. all the
blood examination are performed outside the prison, and
require time-expensive procedures to be activated) which
translate into long time span between the HCV test pre-
scription and its execution. As a consequence, despite it
should be mandatory to test for hepatitis viruses and HIVvite vs HCV Ab negative patients
HCV pos N=156 N(%) p p*




12 (7.69) 95% CI 1.2-3.4







tionality and age as independent variables.
Figure 1 Flow diagram that summarizes the data on diagnosis and treatment of patients with HCV infection.
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admission, or, even when performed, their results can be
lost during prisoner’s relocation.
Compared to Italian, foreign prisoners showed a lower
prevalence of HCV infection, with African born patients,
among foreigners, demonstrating the highest one, as pub-
lished elsewhere [2]. Not surprisingly, women had a higher
prevalence of HCV infection than men, as higher rates of
Hepatitis B and C, HIV, and sexually transmitted infection,
estimated at 2–10 times that of the general population were
observed among imprisoned women, moreover, women had
a significantly higher prevalence of all medical and psychi-
atric conditions and drug dependence when compared with
imprisoned men [16].
In our study even if only 18% of total HCV-RNA positive
inmates refused the treatment, 35 subjects (26%) eventually
were treated. Twenty per cent were untreated as they did
not had specialist consultation and/or did not complete
diagnostic procedures mainly due to organizing deficit and
logistic problems. An interplay between medical and secur-
ity staff should be implemented, in order to better organize
the management of health needs of patients. Even if on 35
patients only, a 43% of SVR was observed, value that is
comparable to data of SVR reported in the literature [17],
confirming that in prison HCV treatment is an important
option to be offered to inmates. HCV prognosis is worse ifnot appropriately treated, as evidenced by reduced mortal-
ity in patients successfully treated [18]. In a recent study
conducted in Texas, end stage liver disease mortality in
prison population is approximately three times higher
than that of the general population, reflecting elevated
rates of HCV and HIV/HCV co-infection among prisoners
[19]. Finally 14% of our treated subjects, released during
treatment, were lost to follow up. As releasing from jail in
Italy most of times take place with no forewarning, our
patients were released without any therapeutic record and
no practical possibility to continue treatment out of jail.
We strongly suggest Italian correctional system to im-
prove guidelines to release inmates with sanitary records
so that they can continue any treatment once free.
The highest prevalence of HCV infection was observed
among HIV positive patients. HIV-HCV-coinfected patients
have higher levels of serum HCV RNA [20], an accelerated
progression to end stage liver disease and a more rapid de-
velopment of liver fibrosis and cirrhosis compared to those
infected with HCV alone [21], moreover, when treated with
antiretroviral treatment for HIV, they may show a de-
creased immune recovery [22]. Given the complex interplay
of the two virus, HIV and HCV, it should be mandatory
that HIV/HCV confected patients receive appropriate treat-
ment for either HIV and HCV as soon as they need it. To
further complicate HCV treatment in prison setting, an
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virus prevalence among inmates has been described [23],
as result of intravenous drug abuse. Report of patients
with chronic hepatitis C and psychiatric diseases treated
in prison with interferon and ribavirin suggest that the
treatment is possible and can be associated with discrete
rate of virologic success [6,7,9,24]. An integrated approach
with psychiatric support, has been described to favorably
overcome the problem of psychiatric disorders in correc-
tional settings [6] and should be advocated for all HCV
patients with psychiatric co-morbidities.
The principal limitation of this study is represented by
its being a single center study, so that the extent of
generalizability of our findings to the prisoner’s population
thus remains unclear, despite the fact the Opera represents
one of the larger Italian prisons. Data on HCV prevalence
reported by other Italian authors are slightly higher than
the ones reported in the present study [3,4]. The reason for
this difference may be explained by the fact that the popu-
lation detained in Milano Opera is different from those of
smaller prisons, as in Milano Opera are detained those
prisoner sentenced for a period longer than three years col-
lected from all the Country for different major crimes (that
are not strictly associated with illicit drug abuse) and in
smaller prisons are detained prisoners for minor offences
(usually intravenous drug abusers). Moreover, despite
roughly 30% of patients restricted at the time of survey
were not test for HCV infection, demographic differences
between those tested and not tested were not observed,
not altering the reproducibility of the data. Other studies
[3,4] report data on a subset of the examined population
(less than 50%) and this might have biased the reproduci-
bility of the results. Another limitation is the absence of ad-
equate follow up as a longer observation period, including
also released patients, would have been useful to evaluate
the response rate to treatment.Conclusion
The present and other studies evidence that the proportion
of patient in a prison setting receiving diagnosis and treat-
ment for HCV infection remain low. The weight of HCV
infection among HIV positive patients is worrisome, as they
often can not be treated due severe immunosuppression
and share the worse prognosis. An integrated health care
taskforce should be encouraged and reinforced, as manage-
ment of treatment of chronic hepatitis C requires the
participation of specialists (hepatologist, infectious disease
specialist, radiologist, psychiatrists) as well as primary care
doctors and nurses.
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